Companies Inivata

Inivata is a  leader in liquid biopsy


Inivata’s liquid biopsy products provide essential genetic insights into cancer patients’ disease with a simple blood test. By tracking changes in the genetic material circulating in a patient’s blood, Inivata’s tests can not only diagnose a patient with cancer, but also direct physicians to the most appropriate therapy and allows monitoring of a patient’s disease during and after treatment.

Inivata was acquired by the leading oncology diagnostics company NeoGenomics in May 2021.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More